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Tight glycaemic control can be implemen-
ted in the acute medical unit outside the
intensive care setting with similar efficacy
and risks of hypoglycaemia as those seen
in ICU studies.30 However, optimal gly-
caemic control in COPD remains unclear
and ICU studies have shown us that
intensive strategies should not be adopted
without rigorous testing in multicentre
clinical trials.
In their paper, Chakrabarti and collea-
gues wisely steer clear of discussing the
sticky issue of glycaemic control during
COPD exacerbations. Rather they con-
centrate on the interesting finding that
blood glucose ,7 mM in combination
with respiratory rate ,30/min predicted
a successful outcome from NIV in 97% of
patients with acute hypercapnic respira-
tory failure. Treatment failure was more
likely (but not inevitable) in those with
respiratory rate .30/min and hypergly-
caemia. If their findings are confirmed in
other patient cohorts, this simple prog-
nostic index could support discussions
with COPD patients and their families
prior to initiation of NIV and allow
targeting of more intensive monitoring
and treatment for those at greater risk of
NIV failure. However, measurement of
blood glucose is not currently part of
NICE/BTS (National Institute for Health
and Clinical Excellence/British Thoracic
Society) guidelines for the management
of COPD exacerbations,31 and data about
blood glucose were not collected in the
2008 national COPD audit. This paper
adds to the growing evidence that
hyperglycaemia is important during
COPD exacerbations and supports inclu-
sion of blood glucose assessment in
future recommendations. However, it
does not clarify underlying mechanisms
or make the case for tight glycaemic
control, both of which require further
study.
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Identification of those at risk
after acute pulmonary embolism
Andrew J Fisher, Paul A Corris
It is well recognised by hands-on clin-
icians that patients who present acutely
with haemodynamic compromise and
hypotension with a systolic pressure of
,90 mm Hg due to acute pulmonary
embolism (PE) have a poor prognosis.
This is reflected in current British
Thoracic Society guidelines in the manage-
ment of acute PE which recommend
Northern Pulmonary Vascular Unit, Freeman Hospital and
Institute of Cellular Medicine, The Medical School,
Newcastle University, Newcastle upon Tyne, UK
Correspondence to: Professor A J Fisher, Institute of
Cellular Medicine, The Medical School, Newcastle
University, Newcastle upon Tyne NE2 4HH, UK;
a.j.fisher@newcastle.ac.uk
Editorial
832 Thorax October 2009 Vol 64 No 10
group.bmj.com on March 8, 2010 - Published by thorax.bmj.comDownloaded from 
aggressive interventions in this population,
with thrombolysis as first-line treatment.1
However, stratification of mortality
and morbidity risk in normotensive
patients who present with acute PE is
less clear. Demonstration of right ventri-
cular dysfunction or dilatation on either
echocardiography or spiral HRCT scan-
ning of the chest has been used as a
potential indicator of those requiring
more aggressive treatment even if normo-
tensive. Immediate availability of these
modalities is not universal, and a simpler
way of identifying those patients at
highest risk of adverse events and mortal-
ity remains critical as the inpatient
mortality rate for normotensive patients
with acute PE is approximately 10%.2 A
number of previous studies have
attempted to identify biomarkers which
have prognostic power in patients with
acute PE. Many of these studies have
focused on cardiac biomarkers including
the troponins and natriuretic peptides
which correlate with right ventricular
dysfunction on echocardiography.3
Whether these systemic biomarkers corre-
late with an increased risk of poor out-
come in patients has been the subject of
debate and, at present, there is no clear
consensus as to the predictive value of
cardiac biomarkers as a guide to risk
stratification in this population.
The recent European Society of
Cardiology guidelines on the diagnosis
and management of acute pulmonary
embolus published in 2008 have gone as
far as including raised levels of the B-type
natriuretic peptides BNP or NT-proBNP
and increased cardiac troponins as mar-
kers of increased risk of a poor outcome
due to PE-related mortality.4
In this issue of Thorax, Lega and
colleagues5 from Quebec, Canada and
Lyons, France present a very comprehen-
sive and methodologically robust meta-
analysis of the prognostic value of
natriuretic peptides and troponins in
acute PE (see page 869). This is an
extremely important piece of work, which
brings together results of a large number
of studies in this area. In addition to
identifying all published studies capable of
evaluation, the authors went to great
lengths to minimise publication bias by
examining all the abstract presentations
at major international respiratory meet-
ings over the last 10 years. In this meta-
analysis, the methodological quality of
the included studies was systematically
reviewed to look for any evidence of
selection bias, information bias, where
the results of cardiac biomarker measure-
ment influenced management and con-
founding bias and where other diseases
such as renal failure or chronic heart
failure may have influenced a result. One
of the difficulties in comparing the results
of the included studies is the range of
different assays used to measure the
natriuretic peptides. Four different assays
were identified and different studies used
different thresholds to define positive and
negative results. In many, the definition
of a positive or negative result was made
at the end of the study based on receiver
operating curve analysis. Despite these
limitations, the results show that raised
levels of B-type natriuretic peptides are
associated with an increased risk of
mortality, serious adverse events and right
ventricular dysfunction after PE. This
association also importantly appears to
hold true for both haemodynamically
stable and unstable patients at presenta-
tion. It also appears to be robust even in
the presence of co-factors such as chronic
heart failure and renal failure. The meta-
analysis did, however, suggest that BNP
measurement appeared to be more accu-
rate than NT-proBNP in correlating with
right ventricular dysfunction.
A previous meta-analysis has been
published in this area. Work by Becattini
and colleagues showed that positive tro-
ponins correlated with right ventricular
myocardial damage and with poor out-
comes after acute PE.6 The paper by Lega
and colleagues adds to the existing litera-
ture by the robustness of its analysis and
the careful search for studies. Specifically,
this meta-analysis also considered the
combined benefit of troponin and
natriuretic peptide measurement. When
a combination of natriuretic peptide and
troponin measurement is used to stratify
risk, the study shows that, in patients
with an increase in natriuretic peptide,
additional elevation of troponins is asso-
ciated with a further increase in PE-related
mortality and serious adverse events.
Importantly, this held true when haemo-
dynamically stable patients were consid-
ered for all-cause mortality with an odds
ratio of 6.9 (confidence interval 2.3 to
20.7) and acute PE-related mortality odds
ratio 8.4 (confidence interval 2.1 to 33.4).
This study offers very useful insights
into risk stratification in normotensive
patients presenting with acute PE. Its
timing is particularly important as there is
growing interest in the outpatient man-
agement of individuals presenting with
acute PE who are haemodynamically
stable. In light of the still high hospital
mortality in this group, it is important
that every effort is made to identify those
at the highest risk who would be unsui-
table for outpatient management. The
measurement of natriuretic peptides and
troponins in this population may not only
be able to identify those patients at
highest risk but also, conversely, if the
natriuretic peptide level is normal, provide
reassurance that a lower risk patient is
eligible for outpatient management. This
is very much the case with supportive
evidence from this study showing that
‘‘natriuretic peptides are particularly help-
ful in identifying low-risk patients’’.
There are caveats on the conclusions
drawn from this meta-analysis. It is
important to recognise that the conclu-
sions give the rationale for a large-scale
prospective multicentre randomised trial
of cardiac biomarkers to stratify risk in PE.
Possible interventions in such a study
could include early thrombolysis in hae-
modynamically stable patients that have
yet to undergo formal assessment for
right ventricular dysfunction, inpatient
anticoagulation and close observation
and outpatient anticoagulation.
The authors should be congratulated
on their valuable contribution to this
important debate, and it is hoped those
involved in research into acute PE will
take this information forward in the
design of clinical trials to provide some
more definitive answers linking risk stra-
tification, intervention and prospective
outcomes in this group of patients.
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